INiTS

What they fund

• Stage: Very early-stage academic spin-offs and innovative scientific/technical ideas ready to found a startup in Vienna. [2]
• Sector: Research, technology, and innovation (FTI), with specific programs for health/life sciences and deep tech. [1]
• Geography: Primarily Vienna-based startups, though international health/life sciences startups are targeted for the Health Hub Vienna. [1]
• Shape: High-growth potential startups requiring commercialization support, business modeling, and early-stage risk-free equity. [1]
• Funding: STARTKapital provides up to €100,000 risk-free equity capital for SCALEup participants. [1]

Investment thesis

INiTS operates as a high-tech business incubator and academic spin-off enabler for the City of Vienna, focusing on research, technology, and innovation (FTI) sectors. [1]

• Academic Commercialization: INiTS supports academic institutions in technology commercialization and the establishment of new spin-off companies from all research institutions in Vienna. [1]
• High-Growth Potential: The incubator targets innovative research/technology-based startups with high growth potential, utilizing a "Collaborative Business Modelling" approach. [1]
• Risk-Free Equity: INiTS provides STARTKapital, a smart financing instrument securing up to €100,000 risk-free equity capital for SCALEup startups at a very early stage. [1]
• Health/Life Sciences: The Health Hub Vienna acceleration program specifically targets international health/life sciences startups in the growth phase to accelerate innovations in the health economy. [1]

Interconnection: The €100k risk-free equity and academic focus imply a pre-seed/seed stage bias, with a strong emphasis on deep tech and biotech rather than consumer software.

Value add

INiTS provides a "Collaborative Business Modelling" approach, tailor-made consulting, training services, and a tightly woven partner network. [1]

Fit verdict: Ideal for academic founders or deep-tech startups needing early-stage validation, business modeling, and risk-free equity in Vienna.

Founder diligence script:

• What is the expected timeline from application to receiving STARTKapital funding?
• How does the "Collaborative Business Modelling" approach differ from traditional incubator mentorship?
• What is the success rate of SCALEup startups in securing follow-on funding from external investors?
• How does INiTS support international health/life sciences startups in navigating the European regulatory landscape?

Portfolio focus

• Lexogen: Biotech company focused on RNA and whole transcriptome studies using Next Generation Sequencing technologies. [1]
• Fluidtime: Developer of qando, the number 1 route planner for public transport in Austria, operating in Mobility-as-a-Service (MaaS). [1]
• Lithoz: Specializes in materials and generative manufacturing systems for 3D printing of bone graft substitutes and advanced ceramics. [1]
• Blue Danube Robotics: Produces safety solutions for human-robot cooperation in mass production using the patented AIRSKIN®. [1]
• KiwiSecurity: Leading manufacturer of video analytics and video control center solutions, transforming video surveillance into a proactive tool. [1]

Notable investments & exits

• MySugr: A startup that benefited from INiTS support in its early days, though specific exit details are not disclosed. [2]
• Jingle: Another startup that utilized INiTS for business model development and investor preparation, with no specific exit information provided. [2]
• Tubolito: A startup that received excellent preparation for investor talks from INiTS, with no specific exit details disclosed. [2]
• Lexogen: A biotech company that has grown significantly since its inception, though no specific exit event is mentioned. [1]
• Fluidtime: Developed qando, a successful app in Austria, indicating a positive outcome, though no specific exit is disclosed. [1]

Strategic implications

INiTS's edge lies in its deep integration with Vienna's academic institutions and its risk-free equity model, which de-risks early-stage deep tech and biotech ventures. [1] The main risk is the potential over-reliance on public funding and academic spin-offs, which may limit exposure to non-academic, high-growth startups. [1] A signal that would change the read is the introduction of a larger, follow-on fund for SCALEup graduates, indicating a shift towards a more traditional VC model. [1]

Where they could go further

INiTS could expand its focus to include non-academic, high-growth startups to diversify its portfolio and reduce reliance on spin-offs. [1] The incubator could develop a stronger network of follow-on investors to support SCALEup graduates beyond the initial €100k risk-free equity. [1] INiTS could enhance its international outreach to attract more global health/life sciences startups to the Health Hub Vienna program. [1] The incubator could explore partnerships with corporate innovators to provide additional resources and market access for its startups. [1]